Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR

Ntoulia, Maria; Stathopoulou, Aliki; Ignatiadis, Michail; Malamos, Nikos N; Mavroudis, Dimitris; Georgoulias, Vassilis; Lianidou, Evi

doi:10.1016/j.clinbiochem.2006.06.009

Cited by 74 publications

(66 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the Kaplan-Meier estimates of overall (P = 0.57) and disease-free survival (P = 0.63) rates for hMAM transcript positive and negative patients were not different. Our results are partially concordant with Ntoulia et al [41], who observed significant differences in the disease-free survival, but not in overall survival, according to hMAM detection.…”

Section: Discussionsupporting

confidence: 93%

“…Thirty eight of 212 (17.9%) patients with operable breast cancer presented hMAM positivebaseline sample. Similarly, Ntoulia et al [41] also reported the expression of hMAM mRNA in 14/101 (13.9%) peripheral blood samples collected before the start of adjuvant chemotherapy, from patients with operable breast cancer. In contrast, Cerveira et al [19] documented peripheral blood hMAM positivity in 41% of breast cancer patients, by one-step RT-PCR.…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Marques

Teixeira

Diamond

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

International audienceHuman mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence. Patients scheduled for adjuvant or neoadjuvant chemotherapy were eligible. Serial blood samples were collected up to 5 years, the first before (neo)adjuvant chemotherapy. hMAM gene expression was analysed by RT-PCR. Specificity was evaluated in blood samples from healthy volunteers. A total of 321 patients were included. The incidence of pre-chemotherapy hMAM-positive samples was similar in patients who latter experienced cancer recurrence (22.4%) and those who remained disease-free (17.9%; = 0.46). Similarly, the mean number of positive follow-up samples was similar in both groups (0.15 ± 0.22 and 0.13 ± 013; = 0.29). Furthermore, there was no difference in disease-free (= 0.63) or overall survival (= 0.57) in patients with and without positive baseline samples or between patients whose follow-up samples were always hMAM negative and those with at least one positive sample. Multivariate survival analysis confirmed that hMAM mRNA detection before or after (neo)adjuvant chemotherapy was not predictive of recurrence. There is no evidence that hMAM mRNA detection at diagnosis or during follow-up predicts for breast cancer recurrence

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 81%

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Marques

Teixeira

Diamond

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Other possible sources include DNA leakage from cells as the result of tumour necrosis or apoptosis, or spontaneous release of DNA into the circulation from primary and metastatic tumours (Stroun et al, 2000). Although many studies have suggested the usefulness of CTC or cell-free DNA as a surrogate marker of subclinical metastasis for breast cancer (Taback et al, 2001;Huang et al, 2006;Ntoulia et al, 2006;Wong et al, 2006;Wülfing et al, 2006;Xenidis et al, 2006;Quintela-Fandino et al, 2006), few studies have looked into the relation between CTC and cell-free DNA in this type of cancer (Schwarzenbach et al, 2004). A combined molecular assessment of the circulating DNA and CTC could improve the evaluation of cancer stage and overall prognosis in breast cancer.…”

mentioning

confidence: 99%

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients

et al. 2009

View full text Add to dashboard Cite

Circulating tumour cells (CTC) and tumour-related methylated DNA in blood have been separately assessed for their utility as a marker for subclinical metastasis in breast cancer. However, no studies have looked into the relation between the both molecular markers in this type of cancer. In this study, we investigated the correlations between total/methylated DNA and CTC in the blood from metastatic breast cancer patients. We simultaneously obtained whole blood, plasma and serum samples from 80 patients and 20 controls. The CellSearch System was used to enumerate CTC in blood samples. Plasma total DNA levels were determined by a QPCR method. Sera were analysed by methylation-specific QPCR for three markers: adenomatous polyposis coli (APC), ras association domain family protein 1A (RASSF1A) and oestrogen receptor 1 (ESR1). Total DNA levels in patients were significantly increased when compared with controls (Po0.001) and correlated with the number of CTC (r ¼ 0.418, Po0.001). Hypermethylation of one or more genes was detected in 42 (53%) serum samples from breast cancer patients and in three (16%) serum samples from controls (P ¼ 0.003). APC was hypermethylated in 29%, RASSF1A in 35% and ESR1 in 20% of breast cancer cases. Detection of a methylated gene in serum was associated with the detection of CTC in blood (P ¼ 0.03). The detection of large amounts of circulating total/ methylated DNA correlated with the presence of CTC in the blood from patients with breast cancer. This can be interpreted in two ways: (a) CTC are a potential source of circulating tumour-specific DNA; (b) high numbers of CTC and circulating methylated DNA are both a phenotypic feature of more aggressive tumour biology.

show abstract

“…This expression is limited to the adult mammary gland (120) and related to mammary gland proliferation and differentiation (110,(121)(122)(123)(124)(125), but is commonly absent in healthy breast tissue samples. The detection frequencies seem to vary (126)(127)(128), sensitivity of qPCR for detection of hMAM mRNA shows a broad range even in metastatic breast cancer (128)(129)(130), imposing doubt on the utility of this marker (118), but a combination of hMAM with survivin and hTERT increases the sensitivity of CTC detection (131), pointing towards the use of multimarker PCR (132). Furthermore, no correlation could be found between the expression of hMAM and nodal state, tumour size and grading (109,121,132).…”

Section: Rt-pcr Marker Genes For Ctc Detectionmentioning

confidence: 99%

“…Silva et al (115) described also the use of EGFR vIII for the detection of CTCs, but the most widely described marker gene, especially in breast cancer analyses for RT-PCR is Mammaglobin A (hMAM) (116)(117)(118). The gene region of hMAM is frequently found to be amplified in breast cancer tissues (119).…”

Section: Rt-pcr Marker Genes For Ctc Detectionmentioning

confidence: 99%

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)

et al. 2016

View full text Add to dashboard Cite

Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR

Cited by 74 publications

References 31 publications

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)

Contact Info

Product

Resources

About